[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-456423-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-456423-en":135},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","shared-decision-making-in-treatment-selection-in-multiple-myeloma-in-spain-the-prismma-study","Shared Decision-Making in Treatment Selection in Multiple Myeloma in Spain - The PRISMMA Study","","Perceptions and experiences of shared decision-making between patients and physicians in multiple myeloma care were examined in Spain through two anonymous online surveys. One survey targeted haematologists and the other MM patients, covering treatment goals, discussion of treatment options, and the decision-making process. Seventy-two haematologists and 76 patients completed the study. Most common goals emphasized prolonging survival with good quality of life, while differences emerged regarding who made the final decision. Findings indicate the need to align second treatment goals and improve shared decision-making to support appropriate treatment selection across disease stages.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/shared-decision-making-in-treatment-selection-in-multiple-myeloma-in-spain-the-prismma-study/456423/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/shared-decision-making-in-treatment-selection-in-multiple-myeloma-in-spain-the-prismma-study/456423.png","ImageObject",300,407,{"name":42,"@type":43},"pop out","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-30",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What was the purpose of the PRISMMA study?","Question",{"text":63,"@type":64},"To explore perceptions of shared decision-making in multiple myeloma treatment selection from both patients and haematologists, focusing on treatment goals, option discussion, and the decision-making process.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study conducted?",{"text":68,"@type":64},"Two anonymous online surveys were used: one for haematologists and one for multiple myeloma patients, each including questions about goals, treatment options discussion, and how decisions were made.",{"name":70,"@type":61,"acceptedAnswer":71},"What treatment goals were most commonly agreed on?",{"text":72,"@type":64},"The most common goal for both patients and haematologists was prolonging survival with a good quality of life, while minimizing hospital visits was reported as the least important goal.",{"name":74,"@type":61,"acceptedAnswer":75},"What key gap did the study identify for shared decision-making?",{"text":76,"@type":64},"Differences appeared in aligning second treatment goals and in perceptions of who made the final treatment decision, indicating a need to improve shared decision-making to support appropriate treatment choices at each stage.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},456423,1790819901,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,119,124,127,131],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},7,40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},8,"Research & Report",30,"research-report",{"id":120,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":122,"slug":123},9,"Religion & Spirituality",20,"religion-spirituality",{"id":122,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":122,"slug":126},"World Cup","world-cup",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":128,"slug":130},10,"Lifestyle","lifestyle",{"id":132,"doc_module":4,"doc_module_name":25,"category_name":133,"show_sort_weight":101,"slug":134},19,"General","general",{"code":4,"msg":86,"data":136},{"doc_id":83,"user_id":137,"nickname":42,"user_avatar":138,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":139,"file_id":140,"file_url":141,"file_type":142,"file_size":143,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":128,"language":144,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":145,"faqs":146,"seo_title":147,"seo_description":12,"update_tm":148,"read_time":149,"preview_page_count":4},962090760408,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","European Journal of Haematology  \nORIGINAL ARTICLE  OPEN ACCESS   \nShared Decision-Making in Treatment Selection in Multiple Myeloma in Spain: The PRISMMA Study  \nValentín Cabañas1  | María Casanova2  | Begoña Barragán3 | Isabel López3 | Anna Raya4 | Belén Santiago-Josefat4   \n1Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain | 2Hospital Costa del Sol Marbella, Marbella, Spain | 3Grupo Español de Pacientes  \ncon Cáncer (GEPAC), Madrid, Spain | 4AMGEN S.A. , Barcelona, Spain Correspondence: Belén Santiago-Josefat ([belen.santiago@amgen.com](belen.santiago@amgen.com))  \nReceived: 23 September 2025 | Revised: 24 October 2025 | Accepted: 28 October 2025  \nFunding: This work was supported by the AMGEN S.A. , Barcelona, Spain.  \nKeywords: evidence-based patient choice | multiple myeloma | selection of treatment | shared decision making  \nABSTRACT  \nIntroduction: Perceptions and experiences of shared decision-making between patients and physicians in multiple myeloma (MM) care are not fully understood. A survey study was conducted to explore these perspectives in Spain.  \nMethods: Two anonymous online surveys, one for haematologists and one for MM patients, were developed. Both included related questions on treatment goals, treatment options discussion and the decision-making process.  \nResults: In total, 72 haematologists and 76 MM patients completed the survey, including 23 in first-line treatment, 37 in secondline or later and 16 with no or unknown treatment line. The most common treatment goal for patients (67%) and haematologists (90%) was to prolong survival with a good quality of life. Becoming symptom-free was the second most important treatment goal for patients and haematologists, followed by extending survival over quality of life for patients and quality of life over survival for haematologists. Both groups agreed that minimising hospital visits was the least important treatment goal. While 92% of haematologists reported discussing treatment goals with their patients, 17% of patients reported having this discussion. Discordances between haematologists and patients emerged in perceptions of who made the final treatment decision.  \nConclusion: While general agreement between patients and haematologists on extending survival with good quality of life was found for the main treatment goal, a need to align second treatment goals and improve the shared decision-making was identified. Addressing these differences is important to ensure the selection of the most appropriate treatment for the individual patient at each stage of their journey.  \n1 | Introduction  \nMultiple myeloma (MM) is a heterogeneous malignancy of monoclonal plasma cells, estimated to globally account for 1% of all cancers [1], and approximately 14% of all haematologic malignancies [2]. Between 2010 and 2016, age-adjusted MM incidence in Spain was found to be 4.09 cases per 100 000 individuals per  \nyear [3], comparable to rates seen in Australia and New Zealand (4.86 cases per 100 000 individuals), and North America (4.74 cases per 100 000 individuals) [2] .  \nOver this period, MM survival rates in Spain improved steadily [3], particularly among patients under 70 years, reflecting significant therapeutic progress achieved over the  \n\n| Abbreviations: AEAL, Spanish association of patients with Lymphoma, Myeloma and Leukaemia; LOT, line of treatment; MM, multiple myeloma; QoL, quality of life; RRMM, relapsed/refractory multiple myeloma; SD, standard deviation; SDM, shared decision-making; SEHH, Spanish Society of Haematology and Haemotherapy. |\n| --- |\n| This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.\u003Cbr>© 2025 The Author(s). European Journal of Haematology published by John Wiley & Sons Ltd. |\n\nEuropean Journal of Haematology, 2026; 116:1","cbCaikJNmp1fuOdM","https://ap.wps.com/l/cbCaikJNmp1fuOdM","pdf",555901,"English","# Introduction\n# Methods\n# Results\n# Conclusion","[{\"question\":\"What was the purpose of the PRISMMA study?\",\"answer\":\"To explore perceptions of shared decision-making in multiple myeloma treatment selection from both patients and haematologists, focusing on treatment goals, option discussion, and the decision-making process.\"},{\"question\":\"How was the study conducted?\",\"answer\":\"Two anonymous online surveys were used: one for haematologists and one for multiple myeloma patients, each including questions about goals, treatment options discussion, and how decisions were made.\"},{\"question\":\"What treatment goals were most commonly agreed on?\",\"answer\":\"The most common goal for both patients and haematologists was prolonging survival with a good quality of life, while minimizing hospital visits was reported as the least important goal.\"},{\"question\":\"What key gap did the study identify for shared decision-making?\",\"answer\":\"Differences appeared in aligning second treatment goals and in perceptions of who made the final treatment decision, indicating a need to improve shared decision-making to support appropriate treatment choices at each stage.\"}]","Shared Decision-Making in Treatment Selection in Multiple Myeloma in Spain - The PRISMMA Study | PDF",1790745984,25]